• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Avanos Medical Inc.

    7/29/25 11:24:56 AM ET
    $AVNS
    Industrial Specialties
    Health Care
    Get the next $AVNS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 11)


    Avanos Medical Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    05350V106

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    05350V106


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    118,440.00
    7Sole Dispositive Power

    4,281,879.00
    8Shared Dispositive Power

    183,017.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,464,896.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.65 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Avanos Medical Inc
    (b)Address of issuer's principal executive offices:

    5405 Windward Parkway, Alpharetta, GA, 30004
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    05350V106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4464896
    (b)Percent of class:

    9.65  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    118440

     (iii) Sole power to dispose or to direct the disposition of:

    4281879

     (iv) Shared power to dispose or to direct the disposition of:

    183017

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $AVNS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVNS

    DatePrice TargetRatingAnalyst
    7/25/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    5/22/2023$31.00Buy
    CL King
    2/24/2022$47.00 → $41.00Overweight
    Keybanc
    1/7/2022$37.00 → $36.00Underweight
    Morgan Stanley
    8/4/2021$45.00 → $41.00Underweight
    Morgan Stanley
    8/4/2021$60.00 → $45.00Overweight → Equal-Weight
    Stephens
    8/4/2021$55.00 → $47.00Overweight
    Keybanc
    More analyst ratings

    $AVNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors

    ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025. Galovan most recently served as Avanos' senior vice president of strategy and corporate development. His background with the company spans 12 years and is highlighted by a proven track record of leading a number of acquisition and divestiture initiatives. Prior to Avanos, he spent 10 years in a variety of strategy, finance, and M&A

    8/5/25 6:45:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical, Inc. Announces Second Quarter 2025 Results

    ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2025 financial results. "Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance in our life-sustaining Specialty Nutrition Systems segment along with continued progress in our opioid-sparing Pain Management & Recovery segment," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our overall execution this quarter was solid, and the steady progress we've made against each of our transfor

    8/5/25 6:30:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical

    ALPHARETTA, Ga., July 31, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), announced today the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC (CMM), a privately held company based in Raleigh, NC. This transaction aligns with Avanos' ongoing transformation, which is focused on advancing its strategic segments in Pain Management & Recovery and Specialty Nutrition Systems. The divested portfolio includes the TriVisc® and GenVisc® 850 injection products, which are indicated for the treatment of osteoarthritis (OA) pain in the knee. These

    7/31/25 4:15:00 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    SEC Filings

    View All

    SEC Form 10-Q filed by Avanos Medical Inc.

    10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)

    8/5/25 4:10:21 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

    8/5/25 6:49:38 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avanos Medical Inc.

    SCHEDULE 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

    7/29/25 11:24:56 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blackford Gary bought $659,300 worth of shares (60,000 units at $10.99), increasing direct ownership by 28% to 91,593 units (SEC Form 4)

    4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    8/15/25 12:02:50 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    Former Interim CEO Greiner Michael covered exercise/tax liability with 24,245 shares, decreasing direct ownership by 11% to 200,019 units (SEC Form 4)

    4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    5/14/25 2:28:49 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    New insider Pickett Jason Marc claimed ownership of 40,113 shares (SEC Form 3)

    3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    4/29/25 3:45:04 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blackford Gary bought $659,300 worth of shares (60,000 units at $10.99), increasing direct ownership by 28% to 91,593 units (SEC Form 4)

    4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    8/15/25 12:02:50 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    Shimer Julie Ann bought $9,925 worth of shares (500 units at $19.85), increasing direct ownership by 1% to 50,090 units (SEC Form 4)

    4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

    3/11/24 5:15:37 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avanos Medical downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight

    7/25/23 6:15:12 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    CL King initiated coverage on Avanos Medical with a new price target

    CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00

    5/22/23 8:52:10 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Keybanc reiterated coverage on Avanos Medical with a new price target

    Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously

    2/24/22 4:48:01 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Leadership Updates

    Live Leadership Updates

    View All

    Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors

    ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025. Galovan most recently served as Avanos' senior vice president of strategy and corporate development. His background with the company spans 12 years and is highlighted by a proven track record of leading a number of acquisition and divestiture initiatives. Prior to Avanos, he spent 10 years in a variety of strategy, finance, and M&A

    8/5/25 6:45:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical, Inc. Welcomes Camille Chang Gilmore as Senior Vice President and Chief Human Resources Officer

    ALPHARETTA, Ga., June 9, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a leading medical technology company focused on delivered innovative healthcare solutions, today announced the appointment of Camille Chang Gilmore as senior vice president and chief human resources officer. In this role, Gilmore will lead all aspects of Avanos' people strategy, including talent acquisition and development, workforce planning, leadership development and employee experience. Her arrival reflects the company's continued commitment to building a workplace where every employee feels val

    6/9/25 7:15:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer

    ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support

    3/17/25 7:30:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avanos Medical Inc.

    SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)

    11/14/24 1:28:34 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

    SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

    2/14/24 11:41:02 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

    SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

    2/13/24 4:58:57 PM ET
    $AVNS
    Industrial Specialties
    Health Care

    $AVNS
    Financials

    Live finance-specific insights

    View All

    Avanos Medical, Inc. Announces Second Quarter 2025 Results

    ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2025 financial results. "Building off our first quarter results, we delivered a strong second quarter anchored by continued healthy performance in our life-sustaining Specialty Nutrition Systems segment along with continued progress in our opioid-sparing Pain Management & Recovery segment," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Our overall execution this quarter was solid, and the steady progress we've made against each of our transfor

    8/5/25 6:30:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical, Inc. Announces First Quarter 2025 Results

    ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

    5/6/25 7:00:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care

    Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

    ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

    4/28/25 7:47:00 AM ET
    $AVNS
    Industrial Specialties
    Health Care